AU2013323596C1 - GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer - Google Patents

GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer Download PDF

Info

Publication number
AU2013323596C1
AU2013323596C1 AU2013323596A AU2013323596A AU2013323596C1 AU 2013323596 C1 AU2013323596 C1 AU 2013323596C1 AU 2013323596 A AU2013323596 A AU 2013323596A AU 2013323596 A AU2013323596 A AU 2013323596A AU 2013323596 C1 AU2013323596 C1 AU 2013323596C1
Authority
AU
Australia
Prior art keywords
cooh
grpr
antagonist
xaa
hooc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013323596A
Other languages
English (en)
Other versions
AU2013323596B2 (en
AU2013323596A1 (en
Inventor
Marion DE JONG HENDRIKS
Theodosia MAINA-NOCK
Berthold Artur NOCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications International SA
Original Assignee
Advanced Accelerator Applications International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications International SA filed Critical Advanced Accelerator Applications International SA
Publication of AU2013323596A1 publication Critical patent/AU2013323596A1/en
Publication of AU2013323596B2 publication Critical patent/AU2013323596B2/en
Priority to AU2018204513A priority Critical patent/AU2018204513C1/en
Priority to AU2019216714A priority patent/AU2019216714B2/en
Assigned to ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL S.A. reassignment ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL S.A. Request for Assignment Assignors: ADVANCED ACCELERATOR APPLICATIONS USA, INC.
Assigned to ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA reassignment ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA Request for Assignment Assignors: Advanced Accelerator Applications International
Application granted granted Critical
Publication of AU2013323596C1 publication Critical patent/AU2013323596C1/en
Priority to AU2021201914A priority patent/AU2021201914B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2013323596A 2012-09-25 2013-09-25 GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer Active AU2013323596C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2018204513A AU2018204513C1 (en) 2012-09-25 2018-06-21 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
AU2019216714A AU2019216714B2 (en) 2012-09-25 2019-08-16 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
AU2021201914A AU2021201914B2 (en) 2012-09-25 2021-03-26 GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705513P 2012-09-25 2012-09-25
US61/705,513 2012-09-25
PCT/US2013/061712 WO2014052471A1 (en) 2012-09-25 2013-09-25 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018204513A Division AU2018204513C1 (en) 2012-09-25 2018-06-21 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer

Publications (3)

Publication Number Publication Date
AU2013323596A1 AU2013323596A1 (en) 2015-04-02
AU2013323596B2 AU2013323596B2 (en) 2018-03-22
AU2013323596C1 true AU2013323596C1 (en) 2020-10-15

Family

ID=49887190

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013323596A Active AU2013323596C1 (en) 2012-09-25 2013-09-25 GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer
AU2018204513A Active AU2018204513C1 (en) 2012-09-25 2018-06-21 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
AU2019216714A Active AU2019216714B2 (en) 2012-09-25 2019-08-16 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
AU2021201914A Active AU2021201914B2 (en) 2012-09-25 2021-03-26 GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2018204513A Active AU2018204513C1 (en) 2012-09-25 2018-06-21 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
AU2019216714A Active AU2019216714B2 (en) 2012-09-25 2019-08-16 Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
AU2021201914A Active AU2021201914B2 (en) 2012-09-25 2021-03-26 GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer

Country Status (19)

Country Link
US (7) US9839703B2 (https=)
EP (2) EP2900279B1 (https=)
JP (4) JP6562838B2 (https=)
KR (2) KR102190005B1 (https=)
AU (4) AU2013323596C1 (https=)
BR (1) BR112015006453B1 (https=)
CA (2) CA3114832A1 (https=)
DK (1) DK2900279T3 (https=)
ES (1) ES2745635T3 (https=)
HR (1) HRP20191620T1 (https=)
HU (1) HUE045724T2 (https=)
IL (4) IL276300B2 (https=)
LT (1) LT2900279T (https=)
MX (1) MX362675B (https=)
PL (1) PL2900279T3 (https=)
PT (1) PT2900279T (https=)
RU (1) RU2693465C9 (https=)
SI (1) SI2900279T1 (https=)
WO (1) WO2014052471A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
ES2745635T3 (es) 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR
EP3015462A1 (en) * 2014-10-29 2016-05-04 OctreoPharm Schiences GmbH Enantiopure chelating agents for chelator coupled pharmaceuticals, corresponding preparation method thereof and chelator coupled pharmaceuticals
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US11857352B2 (en) 2016-09-06 2024-01-02 The Research Foundation For The State University Of New York Positron imaging tomography imaging agent composition and method for bacterial infection
ES2814555T3 (es) 2016-11-28 2021-03-29 Bayer Pharma AG Compuestos de quelato de gadolinio con alta relaxividad para usar en la obtención de imágenes por resonancia magnética
HRP20231458T1 (hr) 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
CA3112060A1 (en) * 2018-10-12 2020-04-16 Advanced Accelerator Applications International Sa Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
WO2021068051A1 (en) * 2018-11-13 2021-04-15 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
KR102934987B1 (ko) 2018-11-23 2026-03-09 바이엘 악티엔게젤샤프트 조영 매체의 제형 및 그의 제조 방법
KR20220063218A (ko) * 2019-09-16 2022-05-17 노파르티스 아게 안정한 농축 방사성 약제학적 조성물
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組
JP2022549258A (ja) * 2019-09-24 2022-11-24 ノバルティス アーゲー セラノスティックスとして使用するための放射性標識grprアンタゴニスト
CA3153267A1 (en) * 2019-12-19 2021-06-24 Hans-Jurgen Wester Modified grpr antagonist peptides for imaging and therapy of cancer
AU2023239751A1 (en) 2022-03-25 2024-09-05 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2026083422A1 (en) * 2024-10-20 2026-04-23 Starget Pharma Ltd Cyclic grpr binding peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) * 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943561A (en) * 1988-11-28 1990-07-24 Merck & Co., Inc. Gastrin releasing peptide antagonist
US5028692A (en) 1989-04-25 1991-07-02 Merck & Co., Inc. Gastrin releasing peptide antagonist
IE903958A1 (en) 1989-11-06 1991-05-08 Erba Carlo Spa Reduced irreversible bombesin antagonists
WO1993016105A1 (en) 1992-02-07 1993-08-19 Merrell Dow Pharmaceuticals Inc. Phenylalanine analogs of bombesin
US5620955A (en) * 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
EP1033372A4 (en) 1997-11-18 2000-10-04 Chugai Pharmaceutical Co Ltd COMPOSITIONS WITH ANTI-TUMOR ACTIVITY
JP5139678B2 (ja) 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
IN2013MN01188A (https=) 2010-11-22 2015-07-10 Piramal Imaging Sa
CA2841238C (en) * 2011-07-08 2019-10-01 Biosynthema Inc. Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors
ES2745635T3 (es) * 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019647A (en) * 1988-05-24 1991-05-28 Merck & Co., Inc. Gastrin releasing peptide antagonist

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABD-ELGALIEL W R ET AL, BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 19, no. 10, doi:10.1021/BC800290C, ISSN 1043-1802, (20081001), pages 2040 - 2048, (20080923) *
DAVID C. HEIMBROOK ET AL, JOURNAL OF MEDICINAL CHEMISTRY, (19910701), vol. 34, no. 7, doi:10.1021/jm00111a027, ISSN 0022-2623, pages 2102 - 2107 *

Also Published As

Publication number Publication date
MX362675B (es) 2019-01-30
AU2013323596B2 (en) 2018-03-22
EP2900279B1 (en) 2019-08-14
JP6562838B2 (ja) 2019-08-21
AU2019216714A1 (en) 2019-09-05
KR102190005B1 (ko) 2020-12-15
WO2014052471A1 (en) 2014-04-03
KR102314293B1 (ko) 2021-10-19
RU2015115529A (ru) 2016-11-20
IL312551A (en) 2024-07-01
JP7534498B2 (ja) 2024-08-14
US12064490B2 (en) 2024-08-20
SI2900279T1 (sl) 2019-12-31
IL276300A (en) 2020-09-30
US20200009276A1 (en) 2020-01-09
ES2745635T3 (es) 2020-03-03
CA2886068C (en) 2021-06-22
IL237844B (en) 2018-01-31
BR112015006453A2 (https=) 2017-09-05
IL276300B2 (en) 2024-10-01
JP2019167365A (ja) 2019-10-03
US11083805B2 (en) 2021-08-10
AU2019216714B2 (en) 2021-04-08
US20220008568A1 (en) 2022-01-13
US20180133349A1 (en) 2018-05-17
JP7358430B2 (ja) 2023-10-10
AU2013323596A1 (en) 2015-04-02
US20240366812A1 (en) 2024-11-07
AU2021201914A1 (en) 2021-04-29
EP2900279A1 (en) 2015-08-05
EP3536347A1 (en) 2019-09-11
KR20150090886A (ko) 2015-08-06
CA2886068A1 (en) 2014-04-03
JP2021191800A (ja) 2021-12-16
JP2023126440A (ja) 2023-09-07
LT2900279T (lt) 2019-11-11
US9839703B2 (en) 2017-12-12
HUE045724T2 (hu) 2020-01-28
KR20200139846A (ko) 2020-12-14
IL312551B2 (en) 2025-12-01
US12064489B2 (en) 2024-08-20
MX2015003772A (es) 2015-11-09
RU2693465C2 (ru) 2019-07-03
US20150265732A1 (en) 2015-09-24
AU2018204513B2 (en) 2019-05-23
JP6997135B2 (ja) 2022-02-04
CA3114832A1 (en) 2014-04-03
IL256649A (en) 2018-02-28
RU2019119378A (ru) 2020-10-23
DK2900279T3 (da) 2019-09-30
US12064491B2 (en) 2024-08-20
AU2018204513C1 (en) 2020-10-15
RU2693465C9 (ru) 2020-08-14
JP2015533119A (ja) 2015-11-19
HRP20191620T1 (hr) 2019-12-13
IL256649B (en) 2020-08-31
IL312551B1 (en) 2025-08-01
IL276300B1 (en) 2024-06-01
PT2900279T (pt) 2019-10-14
AU2021201914B2 (en) 2024-09-05
BR112015006453B1 (pt) 2023-10-17
US20210346528A1 (en) 2021-11-11
PL2900279T3 (pl) 2020-05-18
US20210346529A1 (en) 2021-11-11
AU2018204513A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
AU2021201914B2 (en) GRPR-antagonists for detection, diagnosis and treatment of GRPR-positive cancer
RU2821944C2 (ru) Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания
WO2026058257A1 (en) Grpr binding peptides
Shirmardi et al. Preparation and evaluation of 67Ga-DOTA-Bombesin (7-14) as a tumor scintigraphic agent
Jackson et al. Molecular Imaging of Breast Cancer Tissue via Site-Directed Radiopharmaceuticals

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL S.A.

Free format text: FORMER OWNER(S): ADVANCED ACCELERATOR APPLICATIONS USA, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 MAY 2020

TH Corrigenda

Free format text: IN VOL 34 , NO 14 , PAGE(S) 2098 UNDER THE HEADING ASSIGNMENTS REGISTERED UNDER THE NAME ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL S.A., APPLICATION NO. 2013323596, UNDER INID (71) CORRECT THE APPLICANT NAME TO ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL

PC Assignment registered

Owner name: ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA

Free format text: FORMER OWNER(S): ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 MAY 2020